Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9320MR)

This product GTTS-WQ9320MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9320MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4783MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ2348MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ11486MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ12684MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ14404MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ11035MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ8567MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ5214MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-8015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW